Literature DB >> 9007088

Selegiline and mortality in Parkinson's disease.

C W Olanow1, S Fahn, J W Langston, J Godbold.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 9007088     DOI： 10.1002/ana.410400605

Source DB:  PubMed          Journal:  Ann Neurol        ISSN： 0364-5134            Impact factor:   10.422


× No keyword cloud information.
  3 in total

1.  Investigation by Parkinson's Disease Research Group of United Kingdom into excess mortality seen with combined levodopa and selegiline treatment in patients with early, mild Parkinson's disease: further results of randomised trial and confidential inquiry.

Authors:  Y Ben-Shlomo; A Churchyard; J Head; B Hurwitz; P Overstall; J Ockelford; A J Lees
Journal:  BMJ       Date:  1998-04-18

2.  Selegiline, or the problem of early termination of clinical trials. The clinical questions are not well answered, and probably never will be.

Authors:  M M Breteler
Journal:  BMJ       Date:  1998-04-18

Review 3.  Economic and health-related quality of life considerations of new therapies in Parkinson's disease.

Authors:  L M Rubenstein; A DeLeo; E A Chrischilles
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.